Cytomegalovirus in the transplant setting : Where are we now and what happens next? A report from the International CMV Symposium 2021
© 2022 The Authors. Transplant Infectious Disease published by Wiley Periodicals LLC..
The CMV Symposium in September 2021 was an international conference dedicated to cytomegalovirus (CMV) infection after solid organ or hematopoietic stem cell transplantation. This review provides an overview of the presentations given by the expert faculty, supplemented with educational clinical cases. Topics discussed include CMV epidemiology and diagnosis, the burden of CMV infection and disease, CMV-specific immunity and management of CMV in transplant settings. Major advances in the prevention and treatment of CMV in the past decade and increased understanding of CMV immunity have led to improved patient outcomes. In the future, management algorithms may be individualized based on the transplant recipient's immune profile, which will mark the start of a new era for patients with CMV.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Transplant infectious disease : an official journal of the Transplantation Society - 24(2022), 6 vom: 21. Dez., Seite e13977 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 23.12.2022 Date Revised 11.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/tid.13977 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34786256X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34786256X | ||
| 003 | DE-627 | ||
| 005 | 20231226034836.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/tid.13977 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1159.xml |
| 035 | |a (DE-627)NLM34786256X | ||
| 035 | |a (NLM)36271650 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kotton, Camille N |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cytomegalovirus in the transplant setting |b Where are we now and what happens next? A report from the International CMV Symposium 2021 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.12.2022 | ||
| 500 | |a Date Revised 11.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Authors. Transplant Infectious Disease published by Wiley Periodicals LLC. | ||
| 520 | |a The CMV Symposium in September 2021 was an international conference dedicated to cytomegalovirus (CMV) infection after solid organ or hematopoietic stem cell transplantation. This review provides an overview of the presentations given by the expert faculty, supplemented with educational clinical cases. Topics discussed include CMV epidemiology and diagnosis, the burden of CMV infection and disease, CMV-specific immunity and management of CMV in transplant settings. Major advances in the prevention and treatment of CMV in the past decade and increased understanding of CMV immunity have led to improved patient outcomes. In the future, management algorithms may be individualized based on the transplant recipient's immune profile, which will mark the start of a new era for patients with CMV | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a cellular therapy | |
| 650 | 4 | |a cytomegalovirus immunoglobulin (CMVIG) | |
| 650 | 4 | |a hematopoietic stem cell transplant | |
| 650 | 4 | |a prophylaxis | |
| 650 | 4 | |a solid organ transplant | |
| 650 | 4 | |a treatment | |
| 650 | 4 | |a vaccine | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Torre-Cisneros, Julián |e verfasserin |4 aut | |
| 700 | 0 | |a International CMV Symposium Faculty |e verfasserin |4 aut | |
| 700 | 1 | |a Aguado, José Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Alain, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Baldanti, Fausto |e verfasserin |4 aut | |
| 700 | 1 | |a Baumann, Gabriele |e verfasserin |4 aut | |
| 700 | 1 | |a Boeken, Udo |e verfasserin |4 aut | |
| 700 | 1 | |a de la Calle, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Carbone, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Ciceri, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Comoli, Patrizia |e verfasserin |4 aut | |
| 700 | 1 | |a Couzi, Lionel |e verfasserin |4 aut | |
| 700 | 1 | |a Danziger-Isakov, Lara |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Ruiz, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Girmenia, Corrado |e verfasserin |4 aut | |
| 700 | 1 | |a Grossi, Paolo Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Hirsch, Hans H |e verfasserin |4 aut | |
| 700 | 1 | |a Humar, Atul |e verfasserin |4 aut | |
| 700 | 1 | |a Kamar, Nassim |e verfasserin |4 aut | |
| 700 | 1 | |a Kotton, Camille |e verfasserin |4 aut | |
| 700 | 1 | |a Ljungman, Per |e verfasserin |4 aut | |
| 700 | 1 | |a Malagola, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Mira, Estefania |e verfasserin |4 aut | |
| 700 | 1 | |a Mueller, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Sester, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Teng, Chieh-Lin Jerry |e verfasserin |4 aut | |
| 700 | 1 | |a Torre-Cisneros, Julian |e verfasserin |4 aut | |
| 700 | 1 | |a Ussetti, Piedad |e verfasserin |4 aut | |
| 700 | 1 | |a Westall, Glen |e verfasserin |4 aut | |
| 700 | 1 | |a Wolf, Dana |e verfasserin |4 aut | |
| 700 | 1 | |a Zamora, Marty |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transplant infectious disease : an official journal of the Transplantation Society |d 1999 |g 24(2022), 6 vom: 21. Dez., Seite e13977 |w (DE-627)NLM113005482 |x 1399-3062 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2022 |g number:6 |g day:21 |g month:12 |g pages:e13977 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/tid.13977 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2022 |e 6 |b 21 |c 12 |h e13977 | ||